Since Hsp90 regulates the stability of oncoproteins important in tumor development and progression, in addition to controlling other pathological oligomeric aggregates causing neurodegenerative diseases, Hsp90 inhibitors have been suggested as a potential therapy for misfolding-related diseases [242,243]. The gene discussed is HSP90AB1; the disease is glycogen storage disease VI.